Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/18542
Наслов: Confirmation of the Tumor Response by PET/CT for Lung Cancer Patients Treated with Alectinib: Our Clinical Experience
Authors: Crvenkova S 
Dimitrievska D 
Issue Date: 28-апр-2022
Journal: EC Pulmonology and Respiratory Medicine
Abstract: Background: Anaplastic lymphoma kinase (ALK) rearrangement is identified in approximately 3-7% of all metastatic non-small cell lung cancer (NSCLC) patients, and ALK tyrosine kinase inhibitors (ALKIs) have revolutionized the management of these patients. Purpose: The aim of this study is to present treatment strategy with Alectinib and complete tumor response confirmed by PET/CT for metastatic NSCLC patients at the University Clinic of Radiotherapy and Oncology in Skopje. Material: The primary and point of our institutional study was assessed tumor response, duration of response DoR and CNS efficacy. Tumor response evaluation we performed initial CT of the lung and abdomen or PET/CT (not able to perform for all patients in our country), CT/MRI of the brain and then control previous images including if it possible PET/CT on 3 - 6 mounts, during follow-up visits. Results: We treated nine ALK positive patients with alectinib. We were presented complete tumor response in two of our patents confirmed by PET/CT.
URI: http://hdl.handle.net/20.500.12188/18542
Appears in Collections:Faculty of Medicine: Journal Articles

Files in This Item:
File Опис SizeFormat 
ECPRM-11-00935.pdf“Confirmation of the Tumor Response by PET/CT for Lung Cancer Patients Treated with Alectinib: Our Clinical Experience”1.13 MBAdobe PDFView/Open
Прикажи целосна запис

Page view(s)

71
checked on 1.5.2024

Download(s)

18
checked on 1.5.2024

Google ScholarTM

Проверете


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.